Outlook Therapeutics, Inc. (OTLK) Tops Q2 EPS by 9c

Outlook Therapeutics, Inc. (NASDAQ: OTLK) reported Q2 EPS of ($0.89), $0.09 better than the analyst estimate of ($0.98).

For earnings history and earnings-related data on Outlook Therapeutics, Inc. (OTLK) click here.

You May Also Be Interested In

• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
• LifeSci Capital Starts BlossomHill Therapeutics (BLSM) at Outperform
• Piper Sandler Upgrades Tempus AI Inc (TEM) to Overweight, 'On A Train Back To Upside, We're Not Jumping the Gun'